Checkmate plans to use the proceeds from the financing to support the continued clinical development of CMP-001 in anti-PD-1 refractory melanoma as well as to pursue studies in additional indications, such as front-line melanoma and head and neck squamous cell carcinoma.

Company Information

Company Status

Publicly-held

Industry

Biopharmaceutical

Mailing Address

245 Main St. 2nd Floor
Cambridge, MA 02142
USA

Phone

(617) 682-3625

Website

www.checkmatepharma.com

Email Address

[email protected]

Overview

Checkmate Pharma is developing a new approach for cancer immunotherapy, by specifically activating the immune system to recognize and kill tumor cells throughout the body, without harming normal tissues.

Profile

Social Media

Checkmate Pharmaceuticals Company Twitter Account

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Barry Labinger

Chief Financial Officer

Jon Lieber

Chief Medical Officer

James Wooldridge

Chief Operating Officer

Karen Brennan

Chief Scientific Officer

Art Krieg

VP - Bus. Development

Kleem Chaudhary

VP - General Counsel

Chuck Yon

VP - Operations

Lisa White

VP - Regulatory Affairs

Chris French

VP - Regulatory Affairs

Steven Hamburger

Browse more venture capital transactions:

Prev: 6/11/2020: Protera venture capital transaction
Next: 6/11/2020: Cue Health venture capital transaction

Share this article

News on VC Transactions

We do our best to record all VC transactions involving tech companies. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary